Exelixis | Actif À Court Terme



Current Assets Changement Date
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
Agios Pharmaceuticals USD 965.6M 108.59M 2024-12
Amgen USD 29.03B 2.26B 2024-12
AstraZeneca USD 25.83B 1.67B 2024-12
Bayer EUR 34.44B 1.31B 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Bristol-Myers Squibb USD 29.78B 1.7B 2024-12
Cytokinetics USD 1.11B 89.34M 2024-12
Eisai JPY 761.1B 79.19B 2024-12
Eli Lilly USD 32.74B 1.32B 2024-12
Exelixis USD 1.47B 82.14M 2025-01
Genmab DKK 27.85B 4.16B 2024-12
Glaxosmithkline GBP 17B 301M 2024-12
Incyte USD 3.24B 430.32M 2024-12
Ionis Pharmaceuticals USD 2.62B 93.56M 2024-12
MacroGenics USD 222.2M 65.24M 2024-09
Merck USD 38.78B 1.58B 2024-12
Moderna USD 8.1B 1.57B 2024-12
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 50.36B 7.14B 2024-12
Sanofi 30.08B 589M 2024-06
Takeda JPY 2.75T 299.73B 2024-12
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
Xencor USD 577.6M 4.27M 2024-12



Exelixis Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.